Key result
A patient with both hepatocellular carcinoma and gastric signet-ring cell carcinoma who developed pulmonary tumor thrombotic microangiopathy survived only 3 days after oxygen supplementation.
Why the study?
Pulmonary tumor thrombotic microangiopathy is a rare, fatal cancer-related complication that is hard to confirm antemortem and carries an extremely poor prognosis.
Case Report (n=1)
Pulmonary tumor thrombotic microangiopathy (PTTM) should be considered in cancer patients who progress to rapid respiratory failure and pulmonary hypertension, particularly those with multiple tumors.
Pulmonary tumor thrombotic microangiopathy (PTTM) is a rare cancer-related complication characterized by intimal proliferation in the pulmonary small arteries with or without tumor emboli, which can be fatal due to progressive pulmonary hypertension (PH). And PTTM is hard to be confirmed during lifetime; hence, it is vital to pay more attention to high-risk PTTM, which may progress quickly. PTTM patients have an extremely poor prognosis. Here, we have reported a case of a patient with both hepatocellular carcinoma (HCC) and gastric signet-ring cell carcinoma who presented with dyspnea and died rapidly and was diagnosed with suspected PTTM. In addition, we have reviewed some related literature. This patient showed a poorer prognosis, with a survival time of only 3 days after oxygen supplementation (very poor compared to the average level of PTTM patients caused by gastric carcinoma only, which was 18 days according to our summary). Besides, respiratory discomfort is the main symptom of PTTM. Abnormal pulmonary imaging was reported with the appearance of septal thickening, ground-glass opacities, small nodules, pleural effusion, and a tree-in-bud pattern in PTTM patients. No effective therapeutic options have been established for PTTM. PTTM should be considered in patients with cancer who progress to rapid respiratory failure and PH, especially in patients with multiple tumors whose condition is more likely to deteriorate quickly.
No takes yet. Share an insight, caveat, or question.
Shen et al. (2021) conducted a case report in Pulmonary tumor thrombotic microangiopathy (PTTM) (n=1). Oxygen therapy and supportive care was evaluated on Survival time after oxygen supplementation. A patient with both hepatocellular carcinoma and gastric signet-ring cell carcinoma who developed pulmonary tumor thrombotic microangiopathy survived only 3 days after oxygen supplementation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: